Lizhu Liang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lizhu Liang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Chipeng Guo
Department of Dermatology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
1 shared publication - Guozhen Tan
Department of Dermatology, Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou China
1 shared publication - Jingang Huang
Medical Research Center, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong‐Hong Kong Joint Laboratory for RNA Medicine Sun Yat‐Sen Memorial Hospital, Sun Yat‐Sen University Guangzhou China
1 shared publication - Jingbin Zheng
Medical Research Center, Sun Yat‐Sen Memorial Hospital Sun Yat‐Sen University Guangzhou China
1 shared publication - Liangchun Wang
Department of Dermatology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
1 shared publication - Xiaonan Qiu
Department of Dermatology, Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou China
1 shared publication
Latest Publications
- 31 May 2023
- Published by Wiley in The FASEB Journal
- Vol. 37 (7) , e23015
UCHL1 aggravates skin fibrosis through an IGF ‐1‐induced Akt/ mTOR / HIF ‐1α pathway in keloid
Keloid is a heterogeneous disease featured by the excessive production of extracellular matrix. It is a great challenge for both clinicians and patients regarding the exaggerated and uncontrolled outgrowth and the therapeutic resistance of the disease. In this study, we verified that UCHL1 was drastically upregulated in keloid fibroblasts. UCHL1 had no effects on cell proliferation and migration, but instead promoted collagen I and α‐SMA expression that was inhibited by silencing UCHL1 gene and by adding in LDN‐57444, a pharmacological inhibitor for UCHL1 activity as well. The pathological process was mediated by IGF‐1 promoted Akt/mTOR/HIF‐1α signaling pathway because inhibition of any of them could reduce the expression of collagen I and α‐SMA driven by UCHL1 in fibroblasts. Also, we found that UCHL1 expression in keloid fibroblasts was promoted by M2 macrophages via TGF‐β1. These findings extend our understanding of the pathogenesis of keloid and provide potential therapeutic targets for the disease.
- 31 May 2023
- Published by Wiley in The FASEB Journal
- Vol. 37 (7) , e23015
UCHL1 aggravates skin fibrosis through an IGF ‐1‐induced Akt/ mTOR / HIF ‐1α pathway in keloid
Keloid is a heterogeneous disease featured by the excessive production of extracellular matrix. It is a great challenge for both clinicians and patients regarding the exaggerated and uncontrolled outgrowth and the therapeutic resistance of the disease. In this study, we verified that UCHL1 was drastically upregulated in keloid fibroblasts. UCHL1 had no effects on cell proliferation and migration, but instead promoted collagen I and α‐SMA expression that was inhibited by silencing UCHL1 gene and by adding in LDN‐57444, a pharmacological inhibitor for UCHL1 activity as well. The pathological process was mediated by IGF‐1 promoted Akt/mTOR/HIF‐1α signaling pathway because inhibition of any of them could reduce the expression of collagen I and α‐SMA driven by UCHL1 in fibroblasts. Also, we found that UCHL1 expression in keloid fibroblasts was promoted by M2 macrophages via TGF‐β1. These findings extend our understanding of the pathogenesis of keloid and provide potential therapeutic targets for the disease.